MADRID – The Spanish Agency for Medicines and Health Products (AEMPS) has released its 2024 activities memory, highlighting Spain’s prominent position in global research and key achievements over the past year. The report, coinciding with the agency’s 25th anniversary, details significant progress in medication approvals, clinical trial leadership, and efforts to combat antibiotic resistance.

The AEMPS authorized a total of 1,253 medications for human use in 2024, marking a 30 percent increase compared to the previous year. The agency also processed 47,268 drug variations and assessed 98,860 requests for foreign medicines.

Along with domestic oversight, the AEMPS conducted 410 Inspections carried out during 2024 of laboratories in countries including Taiwan, India, Canada, Romania, and Chile.

AEMPS technicians executed 1,631 activities throughout the year, a 30 percent increase from 2023, to “Ensure the availability of medications of human use.” The agency also processed 1,065 applications for Narcotics transport for travelers, reflecting a 54 percent increase.

The report also highlights the impact of the National Plan against Antibiotic Resistance (Pran). As the project’s inception in 2014,there has been a 13.5 percent decrease in antibiotic consumption in human health and a 69.5 percent decrease in animal health.

Spain’s Leadership in Clinical Trials

“In 2024 Spain again among the world leaders in clinical research and was the country that More studies authorized in the European Union”

The AEMPS emphasized that “In 2024 Spain again among the world leaders in clinical research and was the country that More studies authorized in the European Union,” despite the challenges of implementing the European Regulations for Clinical Tests. Spain has become the leading country in the EU for clinical trials focused on cancer treatments, with 350 oncology trials conducted. The nation also leads in advanced therapy medications, with 52 trials authorized.